Westfield Capital Management Co. LP Has $34.74 Million Holdings in Sarepta Therapeutics Inc (NASDAQ:SRPT)

Westfield Capital Management Co. LP raised its holdings in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 14.3% in the first quarter, Holdings Channel reports. The fund owned 291,487 shares of the biotechnology company’s stock after acquiring an additional 36,385 shares during the quarter. Westfield Capital Management Co. LP’s holdings in Sarepta Therapeutics were worth $34,742,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Sit Investment Associates Inc. lifted its stake in shares of Sarepta Therapeutics by 42.4% in the first quarter. Sit Investment Associates Inc. now owns 22,065 shares of the biotechnology company’s stock worth $2,630,000 after buying an additional 6,575 shares during the last quarter. Mosaic Family Wealth LLC raised its stake in Sarepta Therapeutics by 21.1% during the 1st quarter. Mosaic Family Wealth LLC now owns 2,300 shares of the biotechnology company’s stock valued at $274,000 after purchasing an additional 400 shares during the last quarter. Trexquant Investment LP acquired a new position in Sarepta Therapeutics during the 1st quarter valued at $403,000. Atika Capital Management LLC raised its stake in Sarepta Therapeutics by 15.2% during the 1st quarter. Atika Capital Management LLC now owns 90,000 shares of the biotechnology company’s stock valued at $10,727,000 after purchasing an additional 11,900 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. raised its stake in Sarepta Therapeutics by 32.8% during the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 154,611 shares of the biotechnology company’s stock valued at $18,428,000 after purchasing an additional 38,194 shares during the last quarter.

Sarepta Therapeutics stock traded down $2.41 on Friday, hitting $120.80. The company’s stock had a trading volume of 9,960 shares, compared to its average volume of 679,479. The firm has a market capitalization of $9.14 billion, a PE ratio of -22.26 and a beta of 1.96. The company has a debt-to-equity ratio of 0.35, a current ratio of 12.17 and a quick ratio of 11.15. Sarepta Therapeutics Inc has a one year low of $94.66 and a one year high of $176.50.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.05) by $0.98. The firm had revenue of $87.01 million for the quarter, compared to analyst estimates of $86.92 million. Sarepta Therapeutics had a negative net margin of 124.66% and a negative return on equity of 36.26%. Analysts predict that Sarepta Therapeutics Inc will post -4.33 earnings per share for the current fiscal year.

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,000 shares of the business’s stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $120.00, for a total value of $1,200,000.00. Following the sale, the director now owns 21,717 shares of the company’s stock, valued at approximately $2,606,040. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 6.60% of the company’s stock.

Several equities analysts recently commented on the stock. Morgan Stanley cut their target price on shares of Sarepta Therapeutics from $169.00 to $165.00 and set an “overweight” rating for the company in a research note on Tuesday, May 14th. Cowen reiterated a “buy” rating and set a $213.00 target price on shares of Sarepta Therapeutics in a research note on Sunday, March 31st. Evercore ISI assumed coverage on shares of Sarepta Therapeutics in a research note on Thursday, April 11th. They set an “outperform” rating and a $175.00 target price for the company. ValuEngine cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Finally, Royal Bank of Canada cut their target price on shares of Sarepta Therapeutics from $191.00 to $188.00 and set an “outperform” rating for the company in a research note on Thursday, May 9th. One equities research analyst has rated the stock with a hold rating, twenty-six have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $199.35.

TRADEMARK VIOLATION WARNING: “Westfield Capital Management Co. LP Has $34.74 Million Holdings in Sarepta Therapeutics Inc (NASDAQ:SRPT)” was originally posted by Markets Daily and is owned by of Markets Daily. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.themarketsdaily.com/2019/06/14/westfield-capital-management-co-lp-has-34-74-million-holdings-in-sarepta-therapeutics-inc-nasdaqsrpt.html.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Featured Story: How does new data get added to a blockchain?

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.